Peer-reviewed veterinary case report
Effectiveness of CaniLeish vaccine in native dogs in Mediterranean
By Velez, R et al.·Published in Acta tropica·2020·Hospital Clí, Spain·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of canine leishmaniosis vaccine CaniLeish® under field conditions in native dog populations from an endemic Mediterranean area-A randomized controlled trial.
- Species:
- dog
Plain-English summary
A group of dogs in a Mediterranean area known for leishmaniosis (a disease caused by the Leishmania parasite) were vaccinated with the CaniLeish vaccine to see if it would help prevent infections. After a year, the study found that while the vaccine did not cause severe side effects, it also did not significantly reduce the number of dogs that became infected with the parasite compared to those that were not vaccinated. Both groups had similar rates of active infections, indicating that the vaccine may not be effective in preventing leishmaniosis in dogs living in areas where the disease is common.
People also search for: dog leishmaniosis vaccine effectiveness · CaniLeish vaccine side effects · preventing leishmaniosis in dogs
Abstract
Dog vaccination is considered an effective way of reducing Leishmania infantum infection incidence in the canine population, as well as its transmission to humans. However, the use of partially effective vaccines can have the detrimental effect of "masking" vaccinated asymptomatic carriers, capable of harbouring the parasite and transmitting it to naïve individuals. After eight years on the European market, few studies have been released on CaniLeish® vaccine safety and efficacy. The present study, a one-year randomized CaniLeish® vaccine field trial, was performed in a canine leishmaniosis endemic area and included animals selected from a native dog population (n = 168). No severe adverse reactions were observed in vaccinated dogs (n = 85). Cases of active L. infantum infection were detected by serological, molecular and clinical follow-up of dogs. One-year post-vaccination, no differences in number or severity of L. infantum active infections were observed between study groups (n = 4 in each group). Vaccine-induced cellular immunity, assessed through interferon-γ quantification, showed significantly higher levels of this cytokine one-month post-vaccination in the vaccine group (p < 0.001), but no differences were observed after nine months between trial groups (p = 0.078). These results fail to support the reported CaniLeish® efficacy in the prevention of active L. infantum infection in dogs from endemic areas and naturally exposed to the parasite.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/32035053/